AbbVie gets option on early Argenx cancer drug for $40 mln

April 21 (Reuters) - AbbVie has acquired an option

on an early-stage immuno-oncology drug from biotech company

Argenx, giving the U.S. drugmaker access to a

treatment with the potential to block a...

Read more